Horizant (Gabapentin Enacarbil) Patent Expiration, LOE Window & CMS Spending
Horizant (Gabapentin Enacarbil) by Azurity: FDA Orange Book core substance LOE 2026-11-10 (last listed 2029-06-10), 0 AB generics, $40.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N022399 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2026-11-10 |
| Last Listed Patent or Exclusivity Date | 2029-06-10 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $40.5M |
| 2024 Medicare Part D Spend | $31.8M |
| 2024 Medicaid Spend | $8.7M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 24.3% 2-yr change) |